Journal article

Literature review and evaluation of biomarkers, matrices and analytical methods for chemicals selected in the research program Human Biomonitoring for the European Union (HBM4EU)

  • Sabbioni, Gabriele Research and Transfer Service, Università della Svizzera italiana, Svizzera - Institute of Environmental and Occupational Toxicology, Airolo, Switzerland - Walther-Straub-Institute for Pharmacology and Toxicology, Ludwig-Maximilians-University Munich, Munich, Germany
  • Castaño, Argelia National Centre for Environmental Health, Instituto de Salud Carlos III (ISCIII), Majadahonda, Spain
  • Esteban López, Marta ORCID National Centre for Environmental Health, Instituto de Salud Carlos III (ISCIII), Majadahonda, Spain
  • Göen, Thomas Institute and Outpatient Clinic of Occupational, Social and Environmental Medicine, Friedrich-Alexander Universität Erlangen-Nürnberg (IPASUM), Erlangen, Germany
  • Mol, Hans ORCID Wageningen Food Safety Research, Part of Wageningen University & Research, Wageningen, the Netherlands
  • Riou, Margaux ORCID Department of Environmental and Occupational Health, Santé publique France, The National Public Health Agency, Saint-Maurice, France
  • Tagne-Fotso, Romuald Department of Environmental and Occupational Health, Santé publique France, The National Public Health Agency, Saint-Maurice, France
Show more…
  • 2022
Published in:
  • Environment international. - 2022, vol. 169, p. 107458
English Humans are potentially exposed to a large amount of chemicals present in the environment and in the workplace. In the European Human Biomonitoring initiative (Human Biomonitoring for the European Union = HBM4EU), acrylamide, mycotoxins (aflatoxin B1, deoxynivalenol, fumonisin B1), diisocyanates (4,4′-methylenediphenyl diisocyanate, 2,4- and 2,6-toluene diisocyanate), and pyrethroids were included among the prioritized chemicals of concern for human health. For the present literature review, the analytical methods used in worldwide biomonitoring studies for these compounds were collected and presented in comprehensive tables, including the following parameter: determined biomarker, matrix, sample amount, work-up procedure, available laboratory quality assurance and quality assessment information, analytical techniques, and limit of detection. Based on the data presented in these tables, the most suitable methods were recommended. According to the paradigm of biomonitoring, the information about two different biomarkers of exposure was evaluated: a) internal dose = parent compounds and metabolites in urine and blood; and b) the biologically effective = dose measured as blood protein adducts. Urine was the preferred matrix used for deoxynivalenol, fumonisin B1, and pyrethroids (biomarkers of internal dose). Markers of the biological effective dose were determined as hemoglobin adducts for diisocyanates and acrylamide, and as serum-albumin-adducts of aflatoxin B1 and diisocyanates. The analyses and quantitation of the protein adducts in blood or the metabolites in urine were mostly performed with LC-MS/MS or GC-MS in the presence of isotope-labeled internal standards. This review also addresses the critical aspects of the application, use and selection of biomarkers. For future biomonitoring studies, a more comprehensive approach is discussed to broaden the selection of compounds.
Collections
Language
  • English
Classification
Medicine
License
CC BY-NC-ND
Open access status
gold
Identifiers
Persistent URL
https://n2t.net/ark:/12658/srd1325640
Statistics

Document views: 15 File downloads:
  • Sabbioni_2022_Else_envint (1).pdf: 16